April 10^th, 2025 annual conference Pharmaceuticals – 2025: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2024 and what awaits us in 2025.

Corruption remains one of the key threats to sustainable business development. Corruption scandals demonstrate the disastrous consequences of corruption revelations for companies: multimillion dollar fines, criminal prosecutions of executives, reputational damage and loss of investor confidence.

On 26.12.2024, Federal Law No. 479-FZ was signed, which provides for the obligation for advertising distributors and advertising system operators who distribute advertising in the Internet, aimed at attracting the attention of advertising consumers located in the territory of the Russian Federation, mandatory contributions to the federal budget in the amount of 3% of the amount of income received during the quarter from the sale of services for the distribution of advertising on the ‘Internet’. Quarters are counted from the beginning of the calendar year.

At the 26th session of the Advertising Coordinating Council under the ICAP the Basic Principles of Fair Practices for Bloggers in Advertising in the CIS countries (hereinafter referred to as the “Basic Principles”) were introduced. Basic Principles is an act for self-regulation. The main purpose of Basic Principles is to assist bloggers from CIS countries in complying with advertising legislation.

On 5 December 2024 the results of the annual Pravo-300 law firms’ ranking were announced at an awarding ceremony at The Carlton Hotel in Moscow. This year Lidings expertise is highly praised in 17 key practice areas.

On November 22, 2024, the Government of the Russian Federation (the “Government”) approved Resolution No. 1607 dated November 22, 2024 (the “Resolution”) on the experiment in the territory of the Russian Federation to conduct monitoring of Russian manufacturers of goods which are subject to mandatory marking with means of identification using the state information monitoring system for the circulation of goods subject to mandatory marking with means of identification (the “Experiment”).

More in our update.

Despite the fact that the issue of intellectual property rights turnover is included in the perimeter of antimonopoly regulation, until recently the Russian Antitrust Agency took rather an observant position.

The regulator's position was that the issue of patent infringement is a private legal dispute between original and generic manufacturers, which should not affect the turnover of drugs, particularly the execution of contracts based on the results of public procurement. Only in isolated cases the Russian Antitrust Agency has established the fact of patent infringement and issued a corresponding order on the inadmissibility of anti-competitive practices.

Now the reverse trend has clearly emerged.

More in our update.

On October 23, the Federal Antimonopoly Service of the Russian Federation (the “FAS”) has published recommendations for preventing greenwashing in marketing communications (the “Recommendations”).

Greenwashing is described as actions involving the distribution of false or incorrect environmental statements that mislead consumers regarding the environmental characteristics of goods in order to obtain unjustified advantages.

The Recommendations provide for the concept of environmental statements, their types and requirements for them, as well as the consequences of non-compliance with the requirements for such statements.

We are delighted to announce that Lidings has updated The Pharma Legal Handbook: Russia - practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia.

On April 11, 2024, in Moscow, the annual Pravo.ru conference "Pharmaceuticals – 2024: Legal Issues" will take place. Lidings lawyers traditionally take an active part in the event’s program.

As a strategic partner of the conference, we have endeavored to make the program as comprehensive and useful as possible. Together with experts from the pharmaceutical industry and legal experts, we will discuss current issues in industry regulation, legislative changes, market access, government procurement, and distribution. We will also touch upon marketing and promotion issues, as well as discuss strategies for protecting intellectual property.